WO2000032176A3 - Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis - Google Patents

Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis Download PDF

Info

Publication number
WO2000032176A3
WO2000032176A3 PCT/US1999/028080 US9928080W WO0032176A3 WO 2000032176 A3 WO2000032176 A3 WO 2000032176A3 US 9928080 W US9928080 W US 9928080W WO 0032176 A3 WO0032176 A3 WO 0032176A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
toxoplasmosis
cryptosporidosis
ketosteroids
Prior art date
Application number
PCT/US1999/028080
Other languages
French (fr)
Other versions
WO2000032176A2 (en
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Krupakar Paul Thadikonda
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Priority to AU19235/00A priority Critical patent/AU1923500A/en
Priority to APAP/P/2001/002167A priority patent/AP2001002167A0/en
Priority to CA002352387A priority patent/CA2352387A1/en
Publication of WO2000032176A2 publication Critical patent/WO2000032176A2/en
Publication of WO2000032176A3 publication Critical patent/WO2000032176A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides the use of 17-ketosteroid compounds, e.g., 16α-bromoepiandrosterone, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the 'compounds of the present invention', to treat or prevent Toxoplasmosis or Cryptosporidiosis in patients in need of such treatment or prophylaxis. The formula (1) compounds can also be used to ameliorate or reduce one or more symptoms associated with such infections.
PCT/US1999/028080 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis WO2000032176A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU19235/00A AU1923500A (en) 1998-11-27 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
APAP/P/2001/002167A AP2001002167A0 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis
CA002352387A CA2352387A1 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11012798P 1998-11-27 1998-11-27
US60/110,127 1998-11-27
US12408799P 1999-03-11 1999-03-11
US60/124,087 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23

Publications (2)

Publication Number Publication Date
WO2000032176A2 WO2000032176A2 (en) 2000-06-08
WO2000032176A3 true WO2000032176A3 (en) 2000-12-07

Family

ID=27380789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028080 WO2000032176A2 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis

Country Status (4)

Country Link
AP (1) AP2001002167A0 (en)
AU (1) AU1923500A (en)
CA (1) CA2352387A1 (en)
WO (1) WO2000032176A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DK1955700T3 (en) 1999-09-30 2011-05-23 Harbor Biosciences Inc Therapeutic treatment of androgen receptor-related disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K.R. RASMUSSEN: "Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with Cryptosporidium parvum", J. PARASITOL., vol. 81, no. 3, 1995, pages 429 - 433, XP000922937 *

Also Published As

Publication number Publication date
CA2352387A1 (en) 2000-06-08
AU1923500A (en) 2000-06-19
AP2001002167A0 (en) 2001-06-30
WO2000032176A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
CA2292359A1 (en) Novel azalides and methods of making same
KR100246065B1 (en) Substituted 3-aminoquinuclidines
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
WO2001022953A3 (en) Use of retigabin for treating neuropathic pain
YU62999A (en) C-4"-substituted macrolide derivatives
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
AU684059B2 (en) Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes
GB0102672D0 (en) Compounds
UA41355C2 (en) Agent for treating neuro-aids
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
AU6484199A (en) Carbamate and carbazate ketolide antibiotics
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR0113389A (en) Compounds that inhibit factor xa activity
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2000032176A3 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis
GR3031967T3 (en) Ocular compositions containing steroids and their use in treating glaucoma
AP9801235A0 (en) Erythromycin derivatives.
WO2000002877A3 (en) New pharmaceutically active compounds
CA2331261A1 (en) 2"-deoxy hygromycin derivatives
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders
HU913660D0 (en) The use of imidoazepine derivatives for treating of sleep impairments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/03845

Country of ref document: ZA

Ref document number: 200103845

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2352387

Country of ref document: CA

Ref country code: CA

Ref document number: 2352387

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase